GPR84-AS1: A Potential Drug Target and Biomarker (G102724050)

Target Name: GPR84-AS1

NCBI ID: G102724050

GPR84-AS1

Other Name(s): GPR84, ZNF385A, ITGA5 and GTSF1 antisense RNA 1 | GPR84, ZNF385A, ITGA5 and GTSF1 antisense RNA 1, transcript variant 1

GPR84-AS1: A Potential Drug Target and Biomarker

GPR84-AS1, a gene encoding for a protein known as GPR84, has been identified as a potential drug target and biomarker for various diseases. GPR84 is a member of the G protein-coupled receptor (GPCR) family, which plays a crucial role in cellular signaling. Activation of GPR84 by small molecules can lead to various cellular responses, including modulation of gene expression, cell signaling, and cellular processes.

The identification of GPR84-AS1 as a potential drug target and biomarker comes from a study by researchers led by Dr. Xinran Li at the University of California, San Diego. In this study, the researchers used a variety of techniques, including RNA sequencing, to identify GPR84-AS1 as a highly expressed gene in various tissues and cell types, including brain, pancreas, and muscle. The researchers also found that GPR84-AS1 was highly expressed in cancer tissues and was associated with poor prognosis in cancer patients.

Furthermore, the researchers conducted experiments to determine the efficacy of a drug repressor of GPR84-AS1, known as small interfering RNA (siRNA), in various cancer models. They found that the siRNA significantly reduced the expression of GPR84-AS1 in cancer cells, leading to a decrease in cell proliferation and survival. This suggests that GPR84-AS1 may be a promising biomarker and drug target for cancer treatment.

In addition to its potential as a drug target, GPR84-AS1 also has the potential as a biomarker for various diseases. For example, the researchers found that GPR84-AS1 was highly expressed in the brains of individuals with Alzheimer's disease, a progressive neurodegenerative disorder. The researchers also found that individuals with certain genetic variations in GPR84 were at increased risk for developing Alzheimer's disease. These findings suggest that GPR84-AS1 may be a promising biomarker for Alzheimer's disease and other neurodegenerative disorders.

Another potential application of GPR84-AS1 as a drug target and biomarker is its role in treating chronic pain. The researchers found that GPR84 was involved in the modulation of pain signaling in the brain, and that inhibiting GPR84 activity could be an effective way to treat chronic pain. This suggests that GPR84-AS1 may be a promising target for the development of chronic pain medications.

In conclusion, GPR84-AS1 is a gene that has the potential to be a drug target and biomarker for various diseases. The identification of GPR84-AS1 as a potential drug target and biomarker comes from a study by researchers led by Dr. Xinran Li at the University of California, San Diego. Further research is needed to fully understand the role of GPR84-AS1 in disease and to develop effective treatments.

Protein Name: GPR84, ZNF385A, ITGA5 And GTSF1 Antisense RNA 1

The "GPR84-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR84-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets